Skip to content
MarketScale
‹ Back to IndustriesSciences

Ultramassive Black Hole Discovery Adds New Dimensions To Our Understanding of Space

Recent research from Durham University has uncovered a black hole so massive that it’s difficult to wrap our heads around. Weighing in at a staggering 30 billion times the size of our sun, this ultramassive black hole discovery has scientists questioning our current understanding of the cosmos. What are some of the most important…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Azam Saghir · AstronomyBlack HoleBob RogersCosmic Discovery
Share

Key takeaways

01

Recent research from Durham University has uncovered a black hole so massive that it’s difficult to wrap our heads around.

02

Weighing in at a staggering 30 billion times the size of our sun, this ultramassive black hole discovery has scientists questioning our current understanding of the cosmos.

03

What are some of the most important…

Recent research from Durham University has uncovered a black hole so massive that it’s difficult to wrap our heads around. Weighing in at a staggering 30 billion times the size of our sun, this ultramassive black hole discovery has scientists questioning our current understanding of the cosmos. What are some of the most important takeaways from this discover?

Astronomers at Durham University discovered this colossal black hole using a technique called gravitational lensing – a method involving the observation of how passing light is affected by the black hole’s intense gravitational pull. This breakthrough discovery, published in the journal Monthly Notices of the Royal Astronomical Society, is the first of its kind to utilize gravitational lensing to measure black holes. Experts like Nightingale, one of the chief researchers on this discovery, are left pondering how such a colossal black hole could even have formed in just 13 billion years since the universe’s birth.

On an innovative front, the application of gravitational lensing may open new possibilities for detecting black holes beyond our local universe, illuminating the evolution of these enigmatic phenomena over the course of cosmic history.

Intrigued by the similarities between digital twin methodology and the techniques used in this groundbreaking discovery, Bob Rogers, CEO of Oii.ai and a Ph.D. holder in Physics who has developed digital twins of supermassive black holes in other galaxies, dives deep into the research behind the discovery of this ultramassive black hole and the significance of this discovery on our understanding of the universe and its most explosive tendencies.

Bob’s Thoughts

“When I got my PHD back in the 90s, we were excited to learn that quasars and active galaxies had supermassive black holes at their centers. The newly discovered Abell 1021 BCG ultra massive black hole is estimated to be 10 to a hundred times larger – a whopping one-50th of the mass of our entire Milky Way galaxy and one of the top 10 largest black holes ever discovered.

It took some very special circumstances to create such a huge black hole. There are a few things to note here. First, unlike supermassive black holes that tend to be very bright sources of radio waves, x-rays and or gamma rays, this ultra-massive black hole was spotted because it caused the distortion of the light behind from a galaxy behind it. A phenomenon called microlensing. A great example is the bending of space-time caused by gravity. 

Second, a black hole this large was likely formed by the interaction of three separate galaxies, each of which had its own supermassive black hole. If we’ve spotted one of these, there’s going to be more, and so we might even be able to detect gravitational waves from some of them.

Finally, researchers used a digital twin methodology to infer the mass of the ultra-massive black hole that was causing the observed microlens. As an industrial practitioner of digital twins today, it’s exciting for me to see some of the same techniques we’re using in the supply chain being used in astronomy as well.”

Article written by Azam Saghir.

About the author

AS
Azam Saghir

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

AS
Azam Saghir

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512